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ABSTRACT (249 words) 
 
The 2001 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Report defined five stages of spirometric severity (post-bronchodilator FEV1/FVC 
≥0.7): 0, and 1 (mild) to 4 (very severe). GOLD Stage 0 was defined by chronic cough 
and sputum production or chronic mucus hypersecretion (CMH) alone with preserved 
FEV1/FVC. Subsequently, GOLD 0 was discarded as further evidence of COPD 
development in subjects with GOLD 0 was not more likely to develop. When expanding 
symptomatic burden in GOLD 0 to include other chronic respiratory symptoms, such as 
dyspnea, wheeze, poor quality of life, limited physical activity, and ‘COPD 
exacerbations-like’ events needing health resources, symptomatic smokers with normal 
FEV1 resulted in larger risk of death. We review the evidence supporting a relationship 
between an increased symptom burden, long-term FEV1 decline and development of 
COPD. We also address the evidence for the presence of respiratory symptoms with 
normal FEV1 in smokers as a potential clinical entity. This subset of symptomatic 
patients encompasses a compelling category of smokers with normal spirometry but 
increased risk for poor outcomes. What exactly these symptomatic patients with intact 
FEV1 represent remains unclear. Whether they exemplify smoking-induced just a 
broadening of respiratory abnormalities or a distinct clinical entity that precedes the 
development of COPD or both remains unknown. Other aims, such as providing 
information on pathogenesis and future areas of research, are just as vital. What 
ultimately prevails however is the importance of the public health message to the 
frightening presence of chronic respiratory symptoms in the whole population. 
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…“Would you tell me, please, which way I ought to go from here?" "That depends a 
good deal on where you want to get to." "I don't much care where –" "Then it doesn't 
matter which way you go.”… 
‘Alice in Wonderland’, Lewis Carroll (1832-1898) 
 
The comparison of outcomes between symptomatic individuals with and without 
chronic obstructive pulmonary disease (COPD) is one of the many research questions 
posed in a recent American Thoracic Society (ATS)/European Respiratory Society 
(ERS) Statement 
1
 and represents the main thrust of this pulmonary perspective. We 
review the association between chronic respiratory symptoms, excess decline of FEV1 
and development of COPD and the evidence for a potential new clinical entity in 
individuals with chronic respiratory symptoms and normal spirometry (post-
bronchodilator FEV1/FVC ≥0.7). This subset of patients, roughly similar to the group 
previously labeled ‘Stage 0’ by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD)  
2
, suggests a category of symptomatic smokers with normal 
spirometry but increased risk of poor outcomes. Notwithstanding, it is of note that other 
functional measures of earlier and more subtle changes in small peripheral airways have 
been investigated previously. In the 1960s, a large number of studies were devoted to 
identify susceptible smokers likely to progress to chronic airflow limitation 
3
. In the 
1970s, it was observed in young cigarette smokers that inflammation was evident in the 
small airways in the absence of pulmonary emphysema 
4
. A better understanding of the 
biological mechanisms underlying symptoms in smokers with intact FEV1/FVC should 
improve our ability to treat respiratory symptoms that occur before the development of 
COPD. 
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GOLD 0: SPLENDOR AND DECLINE 
 Traditionally, the typical chronic respiratory symptoms of COPD are cough and sputum 
production, usually referred to as chronic bronchitis or chronic mucus hypersecretion 
(CMH) (phlegm on most days at least 3 months per year for 2 yrs). In the past, these 
were considered common in smokers and strongly related to chronic airflow limitation. 
In the 1980s, a follow-up study in men concluded that the risk of death from COPD was 
associated to the initial degree of airflow limitation but not to CMH, supporting that 
airflow limitation and CMH were largely independent disease processes 
5
. These 
findings were, however, at variance with data from the Copenhagen City Heart Study 
(CCHS) cohort showing an association between CMH and mortality 
6
 and analyses of 
data, at two surveys 5 years apart, that concluded that CMH was significantly associated 
with an excess of FEV1 decline 
7
. 
  
The first 2001 GOLD Report 
2
 stated that a clinical diagnosis of COPD had to be 
confirmed by spirometry, all values referred to post-bronchodilator FEV1/FVC. The 
GOLD document originally defined five spirometric stages (or grades 
8
): 0 and 1 (mild), 
2 (moderate), 3 (severe), and 4 (very severe), a classification also endorsed by the 
ATS/ERS Task Force for COPD 
9
. GOLD ‘Stage 0: At Risk’, namely the sole presence 
of chronic cough and phlegm with normal spirometry, offered a unique opportunity to 
identify individuals at risk for COPD akin to increase awareness among health care 
providers.  
  
Traditionally, the natural history of COPD has been viewed as synonymous with decline 
in FEV1 from early adulthood and throughout life following the seminal work by 
Fletcher and Peto 
10
. However, it was acknowledged that most smokers whose FEV1 is 
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already below the normal range for non-smokers by early adulthood are at risk of death 
due to airflow limitation. Alternatively, the majority of smokers whose FEV1 is still 
above average at this age are unlikely to develop severe airflow limitation. However, 
recent data from three large cohorts have confirmed that approximately half of the 
individuals with airflow limitation followed the hypothesis that implied a rapid FEV1 
decline within normal limits in early adulthood, whereas the other half had a rather 
normal FEV1 decline at this age but started from a low initial value of FEV1 
11
, thus 
supporting the effect of early life events on the likelihood of having airflow limitation in 
adulthood.  
 
CHRONIC RESPIRATORY SYMPTOMS, LONG-TERM FEV1 DECLINE AND 
COPD DEVELOPMENT 
In the 2006 GOLD Revision 
12
, GOLD 0 was no longer included, as there was  
incomplete evidence that the individuals who meet GOLD 0 necessarily progress on to 
GOLD 1+. Nonetheless, the importance of the public health message, to highlight that 
the presence of cough and sputum in the population is not normal, remained unchanged. 
GOLD 0 was discarded based on data from the CCHS cohort 
13
 in which 7.1% of men 
and 4.8% of women (mean age, over 52 years each) had GOLD 0 at baseline with a 
prevalence of 6.1%. After 5 and 15 years, COPD developed in 13.2% and 20.5% of 
smokers with GOLD 0 at enrollment, respectively, although symptoms of cough and 
sputum in unobstructed smokers were associated with an excess lung function decline 
of 19 ml/yr, in addition to the FEV1 reduction observed in unobstructed smokers 
without these symptoms. Despite these findings, the data from this study suggested that 
most of cases of new airflow limitation were observed among subjects without 
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symptoms of cough and sputum and, consequently, it was felt that GOLD Stage 0 was 
of little help in identifying subjects at risk for COPD. 
 
Subsequently, the European Community Respiratory Health Survey Study (ECRHS) 
14
 
determined that the prevalence of GOLD 0 was 11.8% in a randomly selected 
population. Moderate to heavy smoking and second-hand tobacco exposure were 
significantly associated with GOLD 0 and GOLD 1+. Individuals with GOLD 0 
presented the same risks factors, including environmental tobacco exposure and 
childhood respiratory infections, as those with COPD with similar high percentages of 
healthcare resources referred to as ‘breathing problems’. In a cohort of middle-aged and 
elderly subjects with GOLD 0 (non-smokers, 21%), the 10-year incidence of COPD was 
13.5% 
15
. Increasing age, smoking and sputum production but not sex, were risk factors 
for COPD so GOLD 0 appeared to identify individuals at risk for COPD. The study 
from the large Atherosclerosis Risk in Communities (ARIC) cohort 
16
 of smokers and 
non-smokers brought the novelty that patients with GOLD 0, defined by the association 
of any chronic respiratory symptom including breathlessness with normal FEV1, had an 
increased risk of mortality. A parallel study of healthy, middle-aged men, found an 
association between symptoms and risk of death when widening GOLD 0 definition to 
subjects with any respiratory symptom (i.e., dyspnea) than those of CMH alone 
17
. A re-
assessment of the ECRHS cohort alluded to above determined the presence of CMH and 
shortness of breath and future occurrence of COPD 
18
. It was concluded that the 
presence of CMH but not dyspnea identified individuals with a high risk of developing 
chronic airflow limitation and was considered to be an early marker of COPD regardless 
of smoking habits. The prevalence of GOLD 0 was 6.2% in the Proyecto 
Latinoamericano de Investigación en Obstrucción Pulmonar (PLATINO) study 
19
. In 
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that study individuals with CMH had worse lung function and general health conditions 
with more respiratory symptoms, i.e. wheezing and dyspnea, limited physical activity, 
‘COPD exacerbations-like’ events and use of respiratory medications. In the Tucson 
Epidemiological Study of Airway Obstructive Disease (TESAOD) 
20
, CMH at baseline 
significantly increased the risk for incident airflow limitation and all-cause mortality 
among individuals younger than 50 years-old, but not among those subjects older than 
50 years. The conclusion was that CMH with preserved FEV1 in the former group may 
represent an early marker of susceptibility to COPD and all-cause mortality. In the 
Medical Research Council National Survey of Health and Development (MRC-NSHD), 
a prospective study of a representative cohort of women and men 
21
, the prevalence of 
CMH alone among smokers at enrollment increased between ages 36 and 43 from 
7.6±2.0% to 13.0±2.6%, respectively. At these ages, the prevalence of CMH was 
associated with a higher risk of subsequent airflow limitation with a dynamic, 
fluctuating pattern subject to decrease after smoking cessation to levels observed in 
never smokers. Moreover, the longer individuals had symptoms, the higher the FEV1 
decline (Figure 1). The contention was that CMH in middle-aged smokers may 
modulate the early phase of COPD development and reflect activity of the chronic 
airway disease, a hypothesis that was challenged given the background of different 
clinical and developmental phenotypes 
22
.   
 
CLINICAL AND RADIOGRAPHIC CHARACTERISTICS OF SYMPTOMATIC, 
UNOBSTRUCTED INDIVIDUALS  
Recent data from five large cohorts have characterized the clinical and radiographic 
features of symptomatic individuals with normal FEV1. From an urban population-
based study 
23
, two subsets of current smokers with normal spirometry were randomly 
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selected and followed over 3-4 years. In the first group of 59 individuals with normal 
diffusing capacity (DLCO), only 2 subjects (3%) developed significant reductions in 
FEV1/FVC and DLCO. In the second subset with 46 participants with low DLCO at 
baseline, 10 (22%) developed COPD. There were no respiratory clinical and 
radiographic differences between the two groups. 
 
In the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study 
24
, the 
occurrence of ‘exacerbation-like’ events in individuals with and without COPD was  
highlighted. Furthermore, compared with subjects with COPD, those without COPD 
had half the frequency of exacerbations and were independently associated with several 
risk factors (i.e., female sex, presence of wheezing, use of respiratory therapies and poor 
health status). In individuals without COPD, those with exacerbations were more likely 
to have poorer health-related quality of life and missing social activities than those 
without exacerbations. 
 
In parallel, the Genetic Epidemiology of COPD (COPDGene) 
25
 determined similar 
acute events of respiratory disease, more common in curre t and former smokers. In a 
second study from this same COPDGene cohort, a large sample of unobstructed 
subjects was compared with patients with GOLD 1+ and also with a cohort of never 
smokers 
26
. One or more of seven pre-defined respiratory-related impairments (i.e., 
chronic bronchitis, severe respiratory exacerbations, modified Medical Research 
Council score ≥2, computed tomography (CT) percentage emphysema >5% and gas 
trapping >20%, St George’s Respiratory Questionnaire total score >25, and a 6-minute 
walking distance (6MWD) <350 m) were observed in 54% of unobstructed individuals. 
Never smokers without airflow limitation had worse quality of life and lower physical 
Page 8 of 25
For Review Only
 
Pulmonary Perspective 
9
activity and had percentage emphysema or airway-wall thickening on high resolution 
(HR) CT scan. Current smoking was associated with more respiratory symptoms, 
although former smokers had more HRCT findings. Advancing age was associated with 
smoking cessation. Individuals with respiratory impairments were more likely to use 
common respiratory medication and exhibited worse manifestations. Of note that in the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort study 
27
, including participants 
(51% never smokers) without airflow limitation, emphysema-like lung changes on 
cardiac CT were associated with all cause mortality among subjects without airflow 
limitation, particularly among smokers. 
 
Ever or former smokers and never smokers with normal FEV1 from the very recent 
observational Subpopulations and Intermediate Outcome Measures in COPD Study 
(SPIROMICS) cohort 
28
 were investigated. Chronic respiratory symptoms, based on a 
COPD assessment test (CAT) cut-off score ≥10, were observed in 50% of smokers with 
a prevalence of CMH of the order of 33% alone in symptomatic smokers. Importantly, 
the use of CAT, a questionnaire designed for COPD 
29
, provides a broader assessment 
of symptomatic burden than just respiratory symptoms. Compared with asymptomatic 
current or former smokers and never smokers, symptomatic smokers were younger and 
more likely to be current smokers, and reported symptoms of CMH and a history of 
wheezing and asthma than those with lesser symptoms (CAT score <10). Moreover they 
had significantly less physical activity, slightly lower lung function, more respiratory 
exacerbations, and HRCT findings consistent with greater airway wall thickening and 
low percentage emphysema. These differences persisted despite adjustment for reported 
co-morbidities. There were no differences in the spectrum of symptoms between 
symptomatic smokers with normal FEV1 and GOLD 1-2 patients. 
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Interestingly, the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient 
Reported Outcome (EXACT-PRO) 
30
 approach developed to identify and characterize 
exacerbations provides a broader conceptual basis than just respiratory symptoms. 
Finally, the very recent development of the COPD Assessment in Primary Care To 
Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) tool 
(Martinez FJ et al., unpublished data) has suggested that a broader concept of symptoms 
than simple focused respiratory symptoms is useful in identifying undiagnosed COPD. 
These concepts, including the prominent role of fatigue, may provide some insights into 
systemic effects of smoking and explain the greater clinical impact identified by recent 
work on symptomatic, unobstructed smokers than the original GOLD 0 label. 
 
In summary, these data suggest that many individuals with respiratory symptoms but 
without airflow limitation have CT findings consistent with large airway abnormalities 
and these individuals experience significant morbidity and increased health care 
utilization lending credence to the concept that the presence of chronic respiratory 
symptoms in unobstructed smokers represents a clinically significant entity. The weight 
of the evidence would suggest that a greater symptom burden, particularly those 
respiratory in nature, is a risk factor for rapid lung function decline and therefore likely 
represents one form of early COPD, although this likely only represents one pathway 
for COPD development as other individuals without symptoms also go on to develop 
COPD. A study in smokers with GOLD 0-4 from the COPDGene cohort observed a 
significant association between functional small airways disease, assessed by CT-
Parametric Response Mapping (PRM), that identifies areas of non-emphysematous gas 
trapping, and FEV1 decline over 5 years 
31
. Small airways (<2 mm in diameter) are 
known to be the major site of narrowing in patients with COPD 
32
 and disease in the 
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small airways is thought to precede the onset of developing emphysematous lesions 
33
. 
While the signal was attenuated in unobstructed individuals as opposed to those with 
established airflow limitation, CT-assessed small airways disease was still associated 
with more rapid lung function decline in this group. Notably, however, those 
unobstructed individuals with excess small airway abnormality were not more 
symptomatic based on the presence of chronic bronchitis, again reinforcing the multiple 
trajectories towards the development of airflow limitation. This is further emphasized 
by data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints (ECLIPSE) cohort study, in which there was no association between CMH 
and long-term FEV1 decline whereas the presence of pulmonary emphysema was 
associated 
34;35
.  
 
CLINICAL SIGNIFICANCE AND REMAINING QUESTIONS 
The new data on this clinical condition derived from these cohort studies 
24;26;28
 provide 
valuable insights into this condition as a distinct clinical entity, irrespective of whether 
it progresses to COPD. This subset of smokers is predominantly observed in middle-
aged subjects without sex differences. Breathlessness associated with limited physical 
activity and frequent ‘COPD exacerbations-like’ events that require respiratory 
therapies constitute key clinical features. Moreover, it is associated with HRCT 
percentage airway wall thickness changes. Data from long-term longitudinal clinical 
studies described above 
24;26;28
 suggest that symptoms in unobstructed smokers are 
associated with higher risk for the future development of airflow limitation, even in the 
data that ultimately led to the withdrawal of GOLD 0 stage 
13
. However, passage 
through a GOLD 0 stage is not the only pathway to airflow limitation, and many 
patients with GOLD 0 do not necessarily progress to chronic airflow limitation.  
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Whatever the relevance and the robustness of the reported data the list of shortcomings 
or unmet needs (Table 1) is large and overcome in part the established findings. Of note, 
however, that in several of these studies 
26;28
 cough and phlegm production are not 
present in all smokers, suggesting that systemic symptoms (i.e., dyspnea. limited 
physical activity, fatigue) may be more representative of the broad effects of smoking 
per se. One conclusion is that the full breadth of symptoms associated with early lung 
disease in smokers has been underestimated and even unrecognized 
36
. However, it 
could also be that e.g. muscles and the cardiovascular system were affected in these 
smokers. Accordingly, we may probably need to reconsider the strategy of early 
diagnosis and preventative measures by paying more attention to symptoms. It has been 
observed that excess mortality in smokers is largely due to associations with diseases, 
such as renal failure, hypertensive heart disease, and respiratory diseases, not properly 
caused by smoking 
37
. 
 
Alternatively, these unmet needs bring opportunities for future research studies to 
enhance the understanding of the natural history of C PD while further supporting 
preventative and therapeutic approaches. According to a retrospective analysis from 
primary and secondary care cohorts, opportunities to diagnose COPD at an earlier stage 
are being missed, particularly during the 5 years immediately before diagnosis 
38
. These 
needs extend from the selection of appropriate cohorts of participants between 
population-based and disease-specific cohorts, including people with risk factors other 
than tobacco smoking, such as environmental and occupational exposures 
39
. A skillful 
exploitation of tools, such as clinical symptoms (respiratory and non-respiratory) and 
serum biomarkers 
40
 to assess disease activity 
41
,  including sensitive small airways 
disease and exercise tests, may be complementary. Likewise, ‘COPD exacerbations-
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like’ events and coexisting co-morbidities need to be better characterized to provide 
new insights 
42;43
. Furthermore, the different HRCT patterns, combined with novel CT 
volumetric scans and other imaging novelties, have to be better investigated. The 
association between endothelial dysfunction, FEV1 and CT percentage of emphysema in 
former smokers with normal FEV1 suggests that pulmonary vascular disturbances can 
be considerably involved in the development of emphysema 
44
, which supports the 
potential role of pulmonary vessels into the pathogenesis of COPD 
45-47
. Finally, as in 
most smokers respiratory and non-respiratory symptoms may come before airflow 
limitation, we need to reconsider the strategy of early diagnosis and management to 
give first particular attention to symptoms. Last but not least, pharmacologic and non-
pharmacologic therapies to pave the potential of personalized medicine 
48
 need also to 
be re-assessed. 
 
CONCLUSIONS 
It is now time to move beyond GOLD 0 
49
 to decipher the fundamental question 
regarding the short- and long-term clinical significance of the presence of chronic 
respiratory symptoms and preserved lung function. Indeed, the dilemma remains as to 
whether we are simply confronted with an “early phase” of what will become COPD in 
the traditional sense or a separate smoking-related condition which is chronic and 
remains symptomatic without progression to COPD. Indeed it is possible that both 
patterns occur. Research studies targeting this likely distinct condition in the context of 
the systemic effects of smoking by itself should shed light for sure on current 
understanding of the natural history of COPD 
36;37
. 
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LEGEND TO FIGURE 1 
 
The estimated FEV1 decline (Y axis) is influenced by the duration of chronic mucus 
hypersecretion (CMH) between ages 43 and 60–64 years (Y axis) calculated for man (A) 
and woman (B) smokers of average height and weight at age 43. The presence of CMH 
on all three occasions was associated with an additional 10.8 ml/yr FEV1 decline 
between ages 43 and 60–64 years compared with those without CMH on any occasion 
(Reproduced by permission from ref 
21
).
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Table 1. Unmet Needs for Research Studies 
 
- Appropriate population-based cohorts 
- Symptoms (respiratory and non-respiratory); serum biomarkers 
- Health-related quality of life tools: COPD Assessment Test [CAT]; Exacerbations of 
Chronic Pulmonary Disease Tool (EXACT) Patient Reported Outcome (EXACT-
PRO); Saint George’s Respiratory Questionnaire [SGRQ] 
- Sensitive small airways function and exercise (6 min walking distance; incremental 
cycle) tests 
- COPD ‘exacerbation-like’ events: triggers; clinical characteristics; differential 
diagnosis 
- Co-morbidities: cardiovascular; depression; gastroesophageal reflux disease; 
metabolic; skeletal and muscle  
- Computed tomographic (CT) and novel CT volumetric scans and other imaging    
novelties 
- Preventative (smoking cessation; environmental exposures control) and therapeutic 
(pharmacologic and non-pharmacologic) strategies  
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